Lundbeck
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.
Recent news mentioning Lundbeck
- — Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
- — Lundbeck and EVERSANA Announce Strategic Partnership to Advance AI-Powered Commercialization
- — European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
- — European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
- — Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
- — Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S